Biscayne Park

Researchers are evaluating the safety and effectiveness of MANP (modified atrial natriuretic peptide) given by subcutaneous injection to reduce daytime systolic blood pressure in adults with difficult to control or resistant hypertension. This Phase 2 study compares MANP to a placebo in participants who are taking three or more antihypertensive medications with different mechanisms of action. The study focuses on people aged 18 to 80 years who have high blood pressure despite treatment. Participants will receive daily injections of either MANP or a placebo for 42 days. This dose-titration study monitors the response to the treatment over this period. The placebo used is a matched vehicle without the active ingredient. The study aims to observe changes in blood pressure and evaluate potential side effects during and after treatment. During the study, participants will have their blood pressure measured using 24-hour ambulatory blood pressure monitoring to assess changes from baseline. Researchers will also monitor and record any adverse events, serious adverse events, and treatment-emergent adverse events for up to four weeks after the treatment ends, which totals approximately 10 weeks of follow-up. These assessments help determine the safety and efficacy of MANP in this population.